InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

ENGN Clue Score29
Canada (Federal Level) Fiscal year ends October CIK 0001980845
$1.73 -2.81% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.73 −91.35% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 Nov 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−19.4Net income−24.5EPS, diluted44.30Fiscal year 2023Operating income−26.1Net income−99.9EPS, diluted151.22Fiscal year 2024Operating income−62.3Net income−55.1EPS, diluted1.46Fiscal year 2025Operating income−123.2Net income−117.3EPS, diluted2.29
FY2022FY2023FY2024FY2025
Operating income −19.4 −26.1 −62.3 −123.2
Net income −24.5 −99.9 −55.1 −117.3
Growth
EPS, diluted 44.30 151.22 1.46 2.29

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−17.6Capital expenditure−0.2Free cash flow−17.7Fiscal year 2023Operating cash flow−24.7Capital expenditure−0.3Free cash flow−25.1Dividends paid0.0Fiscal year 2024Operating cash flow−48.3Capital expenditure−0.9Free cash flow−49.2Fiscal year 2025Operating cash flow−99.2Capital expenditure−1.5Free cash flow−100.7
FY2022FY2023FY2024FY2025
Operating cash flow −17.6 −24.7 −48.3 −99.2
Capital expenditure −0.2 −0.3 −0.9 −1.5
Free cash flow −17.7 −25.1 −49.2 −100.7
Growth
Dividends paid n/a 0.0 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash20.4Shareholders’ equity−76.6Fiscal year 2023Cash81.5Shareholders’ equity72.5Fiscal year 2024Cash173.0Shareholders’ equity272.6Fiscal year 2025Cash50.2Shareholders’ equity167.7
FY2022FY2023FY2024FY2025
Cash 20.4 81.5 173.0 50.2
Shareholders’ equity −76.6 72.5 272.6 167.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending October, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Oct 2022 FY2023 31 Oct 2023 FY2024† 31 Oct 2024 FY2025 31 Oct 2025
Revenue and profit
15.5 16.5 38.3 94.5
4.0 9.6 24.0 28.7
−19.4 −26.1 −62.3 −123.2
Growth
−24.4 −99.9 −55.2 −117.3
0.0 0.0 −0.0 0.0
−24.5 −99.9 −55.1 −117.3
Growth
Per share
44.30 151.22 1.46 2.29
44.30 151.22 1.46 2.29
Growth +241.4% −99.0% +56.8%
0.7 0.7 37.8 51.1
0.7 0.7 37.8 51.1
Growth +5.7% +5,355.1% +35.3%

† The diluted share count jumps at 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 4 of 4 years on file.